Maybe Blarca. is a great drug, just that with hundreds rather than thousands of trial participants I don't believe it will be approved without another full P3 trial to prove efficacy. I agree with you and the odds of EMA approval are at best 20-25% conditionally. Anavex/Missling sat on their hands doing nothing when another trial was called for, 1000 plus participants. I messed up by investing but no longer believe in them. At all. ANNX far better shot but not ALZ.